Based on this information, current clinical indications for SGLT-2 inhibitor therapy have been expanded to include patients with or without diabetes mellitus and chronic kidney disease, chronic kidney disease with or without albuminuria, congestive heart failure regardless of diabetes, and diabetes mellitus and congestive heart failure with preserved or low ejection fraction [38,43]. The gene discussed is SLC5A2; the disease is congestive heart failure.